|
Alias names |
|
Von Hippel-Lindau disease tumor suppressor, G7 protein, pVHL
|
|
Protocol |
|
The antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should titrate the reagent to obtain optimal results. Recommended dilution range for Western blot analysis is 1:500 ~ 1:1, 000.
Recommended starting dilution is 1:500.
|
|
Substrate/Buffer |
|
Liquid in Phosphate-Buffered Saline (pH 7.4) with 0.1% Sodium Azide
|
|
Storage |
|
Can be stored at 4℃ for up to one month, but store at -20℃ for long term storage. Avoid repeated freezing and thawing cycles
|
|
References |
|
Latif, F., et al (1993) Science. 260(5112), 1317-1320
Duan, D.R., et al (1995) Proc.Natl.Acad.Sci. U.S.A. 92(14), 6459-6463
Maxwell, P.H., et al (1999) Nature 399(6733), 271-275
Chales E. Stebbins, et al (1999) Science 284, 455-461
Staller, P. et al (2003) Nature 425, 307-311
|
|
Contents/Specifications |
|
The antibody was purified from mouse ascitic fluids by protein-G affinity chromatography
|
|
Notes |
|
Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele.
VHL has two domains: a roughly 100-residue NH2-terminal domain rich in β sheet (β-domain) and a smaller α-helical domain (α-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).
|